I have been wondering about this too and I'm sure it is covered off in earlier threads, but I went googling anyway.
I managed to find a document produced by the Australian Department of Health titled:
"Compounded medicines and good manufacturing practice (GMP) Guide to the interpretation of the PIC/S guide to GMP for compounded medicinal products" Version 3.0, September 2020
It is here FYI: https://consultations.health.gov.au/tga/compounded-medicines-and-gmp/supporting_documents/consultationcompoundedmedicinesandgoodmanufacturingpracticegmp.DOCX
This section appears relevant and would imply that Zilosul (once approved) would/should stop the compounding of injectable ElmironAppropriate circumstances for compounding medicines
Only prepare a compounded medicine in circumstances where:
•an appropriate commercial product is not available
•a commercial product is not suitable (e.g. if a patient experienced an allergy to an excipient in the commercial product), or
•when undertaking research sanctioned by a recognised human research ethics committee.
The compounding of a medicine (whether prescribed or not) should not take place when it would both:
•be a close formulation to an available and suitable commercial product
•would not be likely to produce a different therapeutic outcome to the commercial product.
In this situation, notify the prescriber that this medicine cannot be compounded under these circumstances.
DYOR - my thoughts only ;-)
- Forums
- ASX - By Stock
- PAR
- research reports and media
research reports and media, page-2006
-
- There are more pages in this discussion • 2,191 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
30.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $104.9M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 33 | 30.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.0¢ | 50010 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 33 | 0.300 |
5 | 176404 | 0.290 |
3 | 38593 | 0.285 |
4 | 114000 | 0.280 |
1 | 29159 | 0.275 |
Price($) | Vol. | No. |
---|---|---|
0.310 | 50010 | 2 |
0.320 | 35000 | 1 |
0.325 | 50366 | 4 |
0.330 | 125773 | 4 |
0.335 | 10000 | 1 |
Last trade - 07.02am 16/07/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
Day chart unavailable
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online